𝔖 Bobbio Scriptorium
✦   LIBER   ✦

L-tryptophan—associated eosinophilic fasciitis prior to the 1989 eosinophilia—Myalgia syndrome outbreak

✍ Scribed by Jonathan R. Hibbs; Barbara Mittleman; Paula Hill; Thomas A. Medsger Jr.

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
435 KB
Volume
35
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

✦ Synopsis

Objective. To investigate the relationship between L-tryptophan (LT) ingestion and eosinophilic fasciitis (EF) occurring prior to the outbreak of eosinophiliamyalgia syndrome in 1989.

Methods. Interviews and record reviews of 45 EF case-patients and 126 polymyositis patients (controls) diagnosed prior to 1988.

Results. Nine case-patients (20%) and no controls recalled taking LT before onset of the disease (odds ratio = 00, 95% confidence interval = 8.3-m). Among EF case-patients, LT ingestion was associated with dyspnea.

Conclusion.

LT ingestion was associated with EF prior to the 1989 outbreak of eosinophilia-myalgia syndrome. Lung abnormalities may be a distinguishing feature of LT-mediated illness.

Eosinophilic fasciitis (EF) is a rare disorder characterized by eosinophilia of peripheral blood and From the NHLBIICHB, National

📜 SIMILAR VOLUMES

The eosinophilia-myalgia syndrome associ
The eosinophilia-myalgia syndrome associated with ingestion of l-tryptophan
✍ Lawrence E. Shulman 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 484 KB 👁 1 views

physicians in New Mexico notified the New Mexico Department of Health and Environment of 3 patients with marked eosinophilia and severe. incapacitating myalgia who had been taking the amino acid L-tryptophan (orally) and whose illness, after thorough clinical evaluation, seemed both unusual and obsc

Absent neutrophil alkaline phosphatase i
Absent neutrophil alkaline phosphatase in the eosinophilia myalgia syndrome associated with L-tryptophan use
✍ Dr. Jeffrry P. Jaffe; Elie Gertner; Wesley Miller 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 1 views

The clinical constellation of leukocytosis, thrombocytosis, and low or absent stainable neutrophil alkaline phosphatase (NAP) is considered characteristic of chronic myelogenous leukemia (CML) [l]. CML with eosinophilic differentiation (eosinophilic leukemia) is well described [2], and leukemia and

Immunogenetic risk and protective factor
Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia-myalgia syndrome and associated symptoms
✍ Okada, Satoshi ;Kamb, Mary L. ;Pandey, Janardan P. ;Philen, Rossanne M. ;Love, L 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

## Abstract ## Objective To assess L‐tryptophan (LT) dose, age, sex, and immunogenetic markers as possible risk or protective factors for the development of LT‐associated eosinophilia–myalgia syndrome (EMS) and related clinical findings. ## Methods HLA–DRB1 and DQA1 allele typing and Gm/Km pheno